|
gptkbp:instanceOf
|
gptkb:immunomodulatory_drug
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
multiple myeloma
2013 (US)
|
|
gptkbp:ATCCode
|
L04AX06
|
|
gptkbp:CASNumber
|
19171-19-8
|
|
gptkbp:chemicalClass
|
glutarimides
phthalimides
|
|
gptkbp:combines
|
gptkb:dexamethasone
gptkb:bortezomib
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:developedBy
|
gptkb:Celgene
|
|
gptkbp:eliminationHalfLife
|
7.5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:has_black_box_warning
|
venous thromboembolism
embryo-fetal toxicity
|
|
gptkbp:has_trade_name
|
gptkb:Pomalyst
gptkb:Imnovid
|
|
gptkbp:hasMolecularFormula
|
C13H11N3O4
|
|
gptkbp:hasSMILES
|
C1CC(=O)NC(=O)C1C2=CC3=C(C=C2)C(=O)NC(=O)3N
|
|
gptkbp:hasUNII
|
Z8NW08YKPM
|
|
gptkbp:IUPACName
|
4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
immunomodulation
anti-angiogenic
inhibits proliferation of myeloma cells
|
|
gptkbp:meltingPoint
|
315-317 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
X (contraindicated)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2103836
42611257
24611141
DB08910
|
|
gptkbp:relatedTo
|
gptkb:thalidomide
gptkb:lenalidomide
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
fatigue
infections
neutropenia
thrombocytopenia
|
|
gptkbp:bfsParent
|
gptkb:Celgene
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
pomolidomide
|